[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2005128551A - SUBSTITUTED N-ARILGETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR APPLICATION AS MEDICINES - Google Patents

SUBSTITUTED N-ARILGETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR APPLICATION AS MEDICINES Download PDF

Info

Publication number
RU2005128551A
RU2005128551A RU2005128551/04A RU2005128551A RU2005128551A RU 2005128551 A RU2005128551 A RU 2005128551A RU 2005128551/04 A RU2005128551/04 A RU 2005128551/04A RU 2005128551 A RU2005128551 A RU 2005128551A RU 2005128551 A RU2005128551 A RU 2005128551A
Authority
RU
Russia
Prior art keywords
alkyl
independently
another
contain
nitrogen atom
Prior art date
Application number
RU2005128551/04A
Other languages
Russian (ru)
Inventor
Лотар ШВИНК (DE)
Лотар ШВИНК
Зигфрид ШТЕНГЕЛИН (DE)
Зигфрид ШТЕНГЕЛИН
Маттиас ГОССЕЛЬ (DE)
Маттиас Госсель
Томас БЕМЕ (DE)
Томас Беме
Герхард ХЕССЛЕР (DE)
Герхард ХЕССЛЕР
Петра ШТАЛЬ (DE)
Петра Шталь
Дирк ГРЕТЦКЕ (DE)
Дирк Гретцке
Original Assignee
Санофи-Авентис Дойчланд Гмбх (De)
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32841665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2005128551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис Дойчланд Гмбх (De), Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх (De)
Publication of RU2005128551A publication Critical patent/RU2005128551A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (17)

1. Соединение формулы (I)1. The compound of formula (I)
Figure 00000001
Figure 00000001
 где R1, R2, независимо друг от друга, представляют собой H, (C1-C8)алкил, -(CR78R79)o-R12, (C1-C4)алкокси-(C1-C4)алкил, (C3-C8)алкенил, CO-(C1-C8)алкил, -CO-(CH2)o-R12, CO-арилокси-(C1-C4)алкил, COCH=CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22), CO(C(R23)(R24))sO(R25); или R1 и R2 образуют вместе с атомом азота, с которым они связаны, 4-10-членное моно-, би- или спироциклическое кольцо, которое, помимо атома азота, может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей кислород, азот и серу, где гетероциклическая кольцевая система может быть дополнительно замещена F, Cl, Br, CF3, (C1-C6)алкилом, O-(C1-C4)алкилом, (C1-C4)алкокси-(C1-C4)алкилом, гидрокси-(C1-C4)алкилом, (C0-C2)алкиленарилом, оксо, CO(R26), CON(R27)(R28), гидрокси, COO(R29), N(R30)CO(C1-C6)алкилом, N(R31)(R32) или SO2CH3;where R1, R2, independently of one another, are H, (C 1 -C 8 ) alkyl, - (CR78R79) o -R12, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, ( C 3 -C 8 ) alkenyl, CO- (C 1 -C 8 ) alkyl, -CO- (CH 2 ) o -R12, CO-aryloxy- (C 1 -C 4 ) alkyl, COCH = CH (R13), COCC (R14), CO (C (R15) (R16)) q N (R17) (R18), CO (C (R19) (R20)) r CON (R21) (R22), CO (C (R23) ( R24)) s O (R25); or R1 and R2 form, together with the nitrogen atom to which they are attached, a 4-10 membered mono-, bi- or spirocyclic ring, which, in addition to the nitrogen atom, may contain 0-2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system may be further substituted with F, Cl, Br, CF 3 , (C 1 -C 6 ) alkyl, O- (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, (C 0 -C 2 ) alkylene aryl, oxo, CO (R26), CON (R27) (R28), hydroxy, COO (R29) , N (R30) CO (C 1 -C 6 ) alkyl, N (R31) (R32) or SO 2 CH 3 ; o имеет значение 0, 1, 2, 3, 4, 5, 6;o has the value 0, 1, 2, 3, 4, 5, 6; q, r, независимо друг от друга, имеют значение 1, 2, 3;q, r, independently of each other, have a value of 1, 2, 3; s имеет значение 0, 1, 2, 3, 4;s is 0, 1, 2, 3, 4; R13, R14, независимо друг от друга, представляют собой другое фенильное кольцо, которое может содержать 0-1 атом азота;R13, R14, independently of each other, represent another phenyl ring, which may contain 0-1 nitrogen atom; R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, независимо друг от друга, представляют собой H, (C1-C6)алкил;R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, independently of each other, are H, (C 1 -C 6 ) alkyl; R18 представляет собой H, (C1-C6)алкил, CO(R33); илиR18 represents H, (C 1 -C 6 ) alkyl, CO (R33); or R17 и R18, R21 и R22, R27 и R28, R31 и R32, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу;R17 and R18, R21 and R22, R27 and R28, R31 and R32, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0 -1 additional heteroatom selected from the group consisting of N- (C 1 -C 6) -alkyl, oxygen and sulfur; R33 представляет собой 5-10-членную ароматическую кольцевую систему, которая может содержать дополнительный гетероатом, выбранный из группы, включающей азот, кислород и серу, и может быть замещена F, Cl, (C1-C6)алкилом, O-(C1-C8)алкилом;R33 is a 5-10 membered aromatic ring system that may contain an additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and may be substituted with F, Cl, (C 1 -C 6 ) alkyl, O- (C 1 -C 8 ) alkyl; R12 представляет собой OH, O-(C1-C6)алкил, O(C0-C8)алкиленарил, CN, S-(C1-C6)алкил, COO(R80), CON(R81)(R82), 3-12-членное моно-, би- или спироциклическое кольцо, которое может содержать один или несколько гетероатомов, выбранных из группы, включающей N, O и S, и указанное 3-12-членное кольцо может содержать дополнительные заместители, такие как F, Cl, Br, OH, CF3, CN, оксо, O-(C1-C6)алкил, (C1-C4)алкокси-(C1-C4)алкил, (C1-C6)алкил, O-(C0-C8)алкиленарил, (C0-C8)алкиленарил, N(R34)(R35), COCH=CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), CO(C1-C6)алкил, COCOO(C1-C6)алкил, COO(R40), S(O)u(R41);R12 is OH, O- (C 1 -C 6 ) alkyl, O (C 0 -C 8 ) alkylenearyl, CN, S- (C 1 -C 6 ) alkyl, COO (R80), CON (R81) (R82 ), A 3-12 membered mono-, bi- or spirocyclic ring, which may contain one or more heteroatoms selected from the group consisting of N, O and S, and said 3-12-membered ring may contain additional substituents, such as F, Cl, Br, OH, CF 3 , CN, oxo, O- (C 1 -C 6 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, (C 1 -C 6 ) alkyl, O- (C 0 -C 8) alkylene-, (C 0 -C 8) alkylene-, N (R34) (R35) , COCH = CH (R36), (C (R37) (R38)) t (R39 ), CO (C (R37) (R38)) t (R39), CO (C 1 -C 6 ) alkyl, COCOO (C 1 -C 6 ) alkyl, COO (R40), S (O) u (R41) ; t имеет значение 0, 1, 2, 3, 4, 5, 6;t is 0, 1, 2, 3, 4, 5, 6; u имеет значение 0, 1, 2;u has the value 0, 1, 2; R34, R35, R37, R38, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR34, R35, R37, R38, independently of one another, are H, (C 1 -C 8 ) alkyl; or R34 и R35, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6 членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, и может необязательно быть замещенным 1-2 оксогруппами;R34 and R35, optionally together with the nitrogen atom to which they are attached, form a 5-6 membered ring, which, in addition to the nitrogen atom, can also contain 0-1 additional heteroatoms selected from the group consisting of N- (C 1 -C 6 ) alkyl, oxygen and sulfur, and may optionally be substituted with 1-2 oxo groups; R36, R39, независимо друг от друга, представляют собой (C3-C8)циклоалкил, 5-10-членную ароматическую кольцевую систему, которая может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей азот, кислород и серу, и может быть замещена F, Cl, (C1-C6)алкилом, O-(C1-C8)алкилом;R36, R39, independently of each other, are (C 3 -C 8 ) cycloalkyl, a 5-10 membered aromatic ring system that may contain 0-2 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and may be substituted with F, Cl, (C 1 -C 6) alkyl, O- (C 1 -C 8) alkyl; R40 представляет собой H, (C1-C8)алкил, (C2-C6)алкенил, (C0-C8)алкиленарил;R40 represents H, (C 1 -C 8 ) alkyl, (C 2 -C 6 ) alkenyl, (C 0 -C 8 ) alkylenearyl; R41 представляет собой (C1-C6)алкил, 5-10-членную ароматическую кольцевую систему, которая может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей азот, кислород и серу, и может быть замещена F, Cl, (C1-C6)алкилом, O-(C1-C8)алкилом;R41 represents a (C 1 -C 6) -alkyl, 5-10 membered aromatic ring system which may contain 0-2 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be substituted with F, Cl, ( C 1 -C 6 ) alkyl; O- (C 1 -C 8 ) alkyl; R78, R79, независимо друг от друга, представляют собой H, (C1-C8)алкил, гидрокси-(C1-C4)алкил, OH, (C1-C4)алкокси-(C1-C4)алкил;R78, R79, independently of one another, are H, (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, OH, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl; R80, R81, независимо друг от друга, представляют собой H, (C1-C8)алкил;R80, R81, independently of one another, are H, (C 1 -C 8 ) alkyl; R3 представляет собой H, (C1-C6)алкил;R3 is H, (C 1 -C 6 ) alkyl; R4, R5, независимо друг от друга, представляют собой H, (C1-C6)алкил, OH, O-(C1-C6)алкил, O-CO(C1-C6)алкил, S-(C1-C6)алкил;R4, R5, independently of one another, are H, (C 1 -C 6 ) alkyl, OH, O- (C 1 -C 6 ) alkyl, O-CO (C 1 -C 6 ) alkyl, S- ( C 1 -C 6 ) alkyl; R6, R7, R8, R9 представляют собой H; илиR6, R7, R8, R9 are H; or R6 и R7, R8 и R9, независимо друг от друга, необязательно, представляют собой оксо;R6 and R7, R8 and R9, independently of one another, are optionally oxo; n имеет значение 1;n is 1; m имеет значение 1;m is 1; A, B, D, G, независимо друг от друга, представляет собой N, C(R42); илиA, B, D, G, independently of each other, represents N, C (R42); or группы A и B или группы D и G, каждая, представляет собой C(R42) и вместе образуют ортофениленовое звено, в целом образуя 1,4-бизамещенную нафталиновую систему;groups A and B or groups D and G each represent C (R42) and together form an orthophenylene unit, generally forming a 1,4-bisubstituted naphthalene system; R42 представляет собой H, F, Cl, Br, CF3, CN, O-(C1-C6)алкил, O-(C1-C4)алкокси-(C1-C4)алкил, S-(C1-C6)алкил, (C1-C6)алкил, (С0-С8)алкиленарил, O-(C0-C8)алкиленарил, N(R43)(R44), SO2-CH3, CON(R45)(R46), N(R47)CO(R48), CO(R51), -(CR84R85)x-O(R86);R42 represents H, F, Cl, Br, CF 3 , CN, O- (C 1 -C 6 ) alkyl, O- (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, S- ( C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, (C 0 -C 8 ) alkylene aryl, O- (C 0 -C 8 ) alkylene aryl, N (R43) (R44), SO 2 -CH 3 , CON (R45) (R46), N (R47) CO (R48), CO (R51), - (CR84R85) x- O (R86); R43, R44, R45, R46, R47, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR43, R44, R45, R46, R47, independently of one another, are H, (C 1 -C 8 ) alkyl; or R43 и R44, R45 и R46, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу;R43 and R44, R45 and R46, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group including N- (C 1 -C 6 ) alkyl, oxygen and sulfur; R48, R50, R51, независимо друг от друга, представляют собой H, (C1-C8)алкил, арил;R48, R50, R51, independently of one another, are H, (C 1 -C 8 ) alkyl, aryl; R84, R85 представляют собой H;R84, R85 are H; R86 представляет собой H, (C1-C6)алкил;R86 is H, (C 1 -C 6 ) alkyl; x имеет значение 0, 1, 2;x has the value 0, 1, 2; R10 представляет собой H, (C1-C8)алкил;R10 represents H, (C 1 -C 8 ) alkyl; X представляет собой N(R52), связь, C=C, C(R53)(R54), СН2-СН2;X represents N (R52), a bond, C = C, C (R53) (R54), CH 2 —CH 2 ; Y представляет собой O, S, N(R89);Y represents O, S, N (R89); R89 представляет собой H, (C1-C8)алкил;R89 represents H, (C 1 -C 8 ) alkyl; R52, R53, R54, независимо друг от друга, представляют собой H, (C1-C8)алкил;R52, R53, R54, independently of one another, are H, (C 1 -C 8 ) alkyl; E выбран из группы, включающейE is selected from the group including
Figure 00000002
Figure 00000002
Figure 00000003
Figure 00000003
 которые могут необязательно содержать заместители, выбранные из группы, включающей H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)алкил, (C1-C6)алкил, (C2-C6)алкенил, N(R57)(R58), SO2-CH3, CO(R65);which can optionally contain substituents selected from the group consisting of H, F, Cl, Br, OH, CF 3, NO 2, OCF 3, O- (C 1 -C 6) alkyl, (C 1 -C 6) alkyl, (C 2 -C 6 ) alkenyl, N (R57) (R58), SO 2 -CH 3 , CO (R65); R57, R58, независимо друг от друга, представляют собой H, (C1-C8)алкил;R57, R58, independently of one another, are H, (C 1 -C 8 ) alkyl; R65, независимо друг от друга, представляют собой H, (C1-C8)алкил, арил;R65, independently of one another, are H, (C 1 -C 8 ) alkyl, aryl; K представляет собой связь, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C=C, C≡C, SCH2, SO2CH2;K is a bond, O, OCH 2, CH 2 O, S, SO, SO 2, N (R66), N ( R67) CO, CON (R68), (C (R69) (R70)) v, CO, C = C, C≡C, SCH 2 , SO 2 CH 2 ; v имеет значение 1, 2, 3, 4v is 1, 2, 3, 4 R66, R67, R68, R69, R70, независимо друг от друга, представляют собой H, (C1-C8)алкил;R66, R67, R68, R69, R70, independently of one another, are H, (C 1 -C 8 ) alkyl; R11 представляет собой H, (C1-C8)алкил, (C1-C4)алкокси-(C1-C4)алкил, (C3-C8)алкенил, (C3-C8)алкинил, 3-10-членное моно-, би-, три- или спироциклическое кольцо, которое может содержать 0-4 гетероатома, выбранных из группы, включающей кислород, азот и серу, где указанная кольцевая система может быть дополнительно замещена F, Cl, Br, CF3, CN, (C1-C6)алкилом, O-(C1-C8)алкилом, (C1-C4)алкокси-(C1-C4)алкилом, гидрокси-(С1-С4)алкилом, -(C0-C8)алкиленарилом, оксо, CO(R71), CON(R72)(R73), гидрокси, COO(R74), N(R75)CO(C1-C6)алкилом, N(R76)(R77) или SO2CH3;R11 represents H, (C 1 -C 8 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 ) alkynyl, 3-10 membered mono-, bi-, tri- or spirocyclic ring, which may contain 0-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where this ring system may be further substituted by F, Cl, Br, CF 3 , CN, (C 1 -C 6 ) alkyl, O- (C 1 -C 8 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, - (C 0 -C 8 ) alkylene aryl, oxo, CO (R71), CON (R72) (R73), hydroxy, COO (R74), N (R75) CO (C 1 -C 6 ) alkyl, N (R76) (R77) or SO 2 CH 3 ; R71, R72, R73, R74, R75, R76, R77, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR71, R72, R73, R74, R75, R76, R77, independently of one another, are H, (C 1 -C 8 ) alkyl; or R72 и R73, R76 и R77, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, илиR72 and R73, R76 and R77, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group consisting of N- (C 1 -C 6) -alkyl, oxygen and sulfur, or их N-оксиды и физиологически приемлемые соли.their N-oxides and physiologically acceptable salts. 2. Соединение формулы (I) по п.1,2. The compound of formula (I) according to claim 1, где R1, R2, независимо друг от друга, представляют собой H, (C1-C8)алкил, -(CR78R79)o-R12, (C1-C4)алкокси-(C1-C4)алкил, CO-(C1-C8)алкил, -CO-(CH2)o-R12, COCH=CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R23)(R24))sO(R25); или R1 и R2 образуют вместе с атомом азота, с которым они связаны, 4-10-членное моно- или бициклическое кольцо, которое, помимо атома азота, может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей кислород, азот и серу, где гетероциклическая кольцевая система может быть дополнительно замещена F, Cl, CF3, (C1-C6)алкилом, O-(C1-C4)алкилом, (C1-C4)алкокси-(C1-C4)алкилом, (C0-C2)алкиленарилом, оксо, CO(R26), гидрокси, N(R31)(R32) или SO2CH3;wherein R1, R2, independently, represent H, (C 1 -C 8) -alkyl, - (CR78R79) o -R12, (C 1 -C 4) alkoxy- (C 1 -C 4) alkyl, CO - (C 1 -C 8 ) alkyl, -CO- (CH 2 ) o -R12, COCH = CH (R13), COCC (R14), CO (C (R15) (R16)) q N (R17) (R18 ), CO (C (R23) (R24)) s O (R25); or R1 and R2 form, together with the nitrogen atom to which they are attached, a 4-10 membered mono- or bicyclic ring, which, in addition to the nitrogen atom, may contain 0-2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur where the heterocyclic ring system may be further substituted with F, Cl, CF 3 , (C 1 -C 6 ) alkyl, O- (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, (C 0 -C 2 ) alkylene aryl, oxo, CO (R26), hydroxy, N (R31) (R32) or SO 2 CH 3 ; o имеет значение 0, 1, 2, 3, 4;o has the value 0, 1, 2, 3, 4; q имеет значение 1 или 2;q is 1 or 2; s имеет значение 0, 1, 2, 3;s is 0, 1, 2, 3; R13, R14, независимо друг от друга, представляют собой другое фенильное кольцо, которое может содержать 0-1 атом азота;R13, R14, independently of each other, represent another phenyl ring, which may contain 0-1 nitrogen atom; R15, R16, R17, R23, R24, R26, R31, R32, независимо друг от друга, представляют собой H, (C1-C6)алкил;R15, R16, R17, R23, R24, R26, R31, R32, independently of one another, are H, (C 1 -C 6 ) alkyl; R18 представляет собой H, (C1-C6)алкил, CO(C1-C6)алкил; илиR18 represents H, (C 1 -C 6 ) alkyl, CO (C 1 -C 6 ) alkyl; or R17 и R18, R31 и R32, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, выбранное из пирролидина, пиперидина, N-метилпиперазина, морфолина;R17 and R18, R31 and R32, independently of each other, optionally together with the nitrogen atom to which they are attached, form a 5-6 membered ring selected from pyrrolidine, piperidine, N-methylpiperazine, morpholine; R12 представляет собой OH, O-(C1-C6)алкил, O(C0-C8)алкиленарил, CN, 3-10-членное моно- или бициклическое кольцо, которое может содержать 1-3 гетероатома, выбранных из группы, включающей N, O и S, и указанное 3-10 членное кольцо может содержать дополнительные заместители, такие как F, Cl, Br, OH, CF3, CN, оксо, O-(C1-C6)алкил, (C1-C4)алкокси-(C1-C4)алкил, (C1-C6)алкил, (C0-C2)алкиленарил, N(R34)(R35), CO(C1-C6)алкил;R12 represents OH, O- (C 1 -C 6 ) alkyl, O (C 0 -C 8 ) alkylenearyl, CN, a 3-10 membered mono- or bicyclic ring, which may contain 1-3 heteroatoms selected from the group including N, O and S, and the specified 3-10 membered ring may contain additional substituents, such as F, Cl, Br, OH, CF 3 , CN, oxo, O- (C 1 -C 6 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, (C 1 -C 6 ) alkyl, (C 0 -C 2 ) alkylene aryl, N (R34) (R35), CO (C 1 -C 6 ) alkyl; t имеет значение 0, 1, 2, 3, 4, 5, 6;t is 0, 1, 2, 3, 4, 5, 6; u имеет значение 0 или 2;u has a value of 0 or 2; R34, R35, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR34, R35, independently of one another, are H, (C 1 -C 8 ) alkyl; or R34 и R35, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, и может быть замещенным 1-2 оксогруппами;R34 and R35, optionally together with the nitrogen atom to which they are attached, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group consisting of N- (C 1 -C 6 ) alkyl, oxygen and sulfur, and may be substituted with 1-2 oxo groups; R78, R79, независимо друг от друга, представляют собой H, (C1-C8)алкил, гидрокси-(C1-C4)алкил, OH, (C1-C4)алкокси-(C1-C4)алкил;R78, R79, independently of one another, are H, (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, OH, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl; R3 представляет собой H;R3 represents H; R4, R5, независимо друг от друга, представляют собой H, (C1-C6)алкил, OH, O-(C1-C6)алкил, O-CO(C1-C6)алкил;R4, R5, independently of one another, are H, (C 1 -C 6 ) alkyl, OH, O- (C 1 -C 6 ) alkyl, O-CO (C 1 -C 6 ) alkyl; R6, R7, R8, R9 представляют собой H;R6, R7, R8, R9 are H; n имеет значение 1;n is 1; m имеет значение 1;m is 1; A, B, D, G: В представляет собой N, C(R42); и A, D, G представляют собой C(R42);A, B, D, G: B represents N, C (R42); and A, D, G are C (R42); R42 представляет собой H, F, Cl, Br, CF3, CN, O-(C1-C6)алкил, (C1-C6)алкил, SO2-CH3, CON(R45)(R46), N(R47)CO(R48), CO(R51), -(CR84R85)x-O(R86);R42 is H, F, Cl, Br, CF 3 , CN, O- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, SO 2 -CH 3 , CON (R45) (R46), N (R47) CO (R48) , CO (R51), - (CR84R85) x -O (R86); R45, R46, R47, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR45, R46, R47, independently of one another, are H, (C 1 -C 8 ) alkyl; or R45 и R46, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу;R45 and R46, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group consisting of N- (C 1 -C 6 ) alkyl, oxygen and sulfur; R48, R51, независимо друг от друга, представляют собой H, (C1-C8)алкил;R48, R51, independently of one another, are H, (C 1 -C 8 ) alkyl; R84, R85 представляют собой H;R84, R85 are H; R86 представляет собой H, (C1-C6)алкил;R86 is H, (C 1 -C 6 ) alkyl; x имеет значение 0, 1;x has the value 0, 1; R10 представляет собой H, (C1-C8)алкил;R10 represents H, (C 1 -C 8 ) alkyl; X представляет собой N(R52), связь, C=C, C(R53)(R54), СН2-СН2;X represents N (R52), a bond, C = C, C (R53) (R54), CH 2 —CH 2 ; R52, R53, R54, независимо друг от друга, представляют собой H, (C1-C8)алкил;R52, R53, R54, independently of one another, are H, (C 1 -C 8 ) alkyl; E выбран из группы, включающейE is selected from the group including
Figure 00000004
Figure 00000004
 которые могут необязательно содержать заместители, выбранные из группы, включающей H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)алкил, (C1-C6)алкил, (C2-C6)алкенил, N(R57)(R58), SO2-CH3, CO(R65);which may optionally contain substituents selected from the group consisting of H, F, Cl, Br, OH, CF 3 , NO 2 , OCF 3 , O- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, N (R57) (R58), SO 2 -CH 3 , CO (R65); R57, R58, независимо друг от друга, представляют собой H, (C1-C8)алкил;R57, R58, independently of one another, are H, (C 1 -C 8 ) alkyl; R65, независимо друг от друга, представляют собой H, (C1-C8)алкил;R65, independently of one another, are H, (C 1 -C 8 ) alkyl; K представляет собой связь, O, OCH2, CH2O, N(R66), CON(R68), (C(R69)(R70))v, CO, C≡C, SCH2;K represents a bond, O, OCH 2 , CH 2 O, N (R66), CON (R68), (C (R69) (R70)) v , CO, C≡C, SCH 2 ; v имеет значение 1, 2, 3;v has a value of 1, 2, 3; R66, R68, R69, R70, независимо друг от друга, представляют собой H, (C1-C8)алкил;R66, R68, R69, R70, independently of one another, are H, (C 1 -C 8 ) alkyl; R11 представляет собой (C1-C8)алкил, (C1-C4)алкокси-(C1-C4)алкил, 3-10-членное моно-, би-, три- или спироциклическое кольцо, которое может содержать 0-3 гетероатома, выбранных из группы, включающей кислород, азот и серу, где указанная кольцевая система может быть дополнительно замещена F, Cl, Br, CF3, CN, (C1-C6)алкилом, O-(C1-C8)алкилом, -(C0-C2)алкиленарилом, оксо, CO(R71), CON(R72)(R73), гидрокси, N(R75)CO(C1-C6)алкилом, N(R76)(R77) или SO2CH3;R11 is a (C 1 -C 8 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, 3-10 membered mono-, bi-, tri- or spirocyclic ring, which may contain 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein said ring system may be further substituted with F, Cl, Br, CF 3 , CN, (C 1 -C 6 ) alkyl, O- (C 1 - C 8 ) alkyl, - (C 0 -C 2 ) alkylene aryl, oxo, CO (R71), CON (R72) (R73), hydroxy, N (R75) CO (C 1 -C 6 ) alkyl, N (R76) (R77) or SO 2 CH 3 ; R71, R72, R73, R75, R76, R77, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR71, R72, R73, R75, R76, R77, independently of one another, are H, (C 1 -C 8 ) alkyl; or R72 и R73, R76 и R77, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу; илиR72 and R73, R76 and R77, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group including N- (C 1 -C 6 ) alkyl, oxygen and sulfur; or их N-оксиды и физиологически приемлемые соли.their N-oxides and physiologically acceptable salts. 3. Соединение формулы (I) по п.1,3. The compound of formula (I) according to claim 1, где R1, R2, независимо друг от друга, представляют собой H, (C1-C8)алкил, -(CR78R79)o-R12, (C1-C4)алкокси-(C1-C4)алкил, CO-(C1-C8)алкил, -CO-(CH2)o-R12, O(C(R15)(R16))qN(R17)(R18); или R1 и R2 образуют вместе с атомом азота, с которым они связаны, 4-10-членное моно- или бициклическое кольцо, которое, помимо атома азота, может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей кислород и азот, где гетероциклическая кольцевая система может быть дополнительно замещена F, (C1-C6)алкилом, (C1-C4)алкокси-(C1-C4)алкилом, оксо, CO(R26), гидрокси, N(R31)(R32);where R1, R2, independently of one another, are H, (C 1 -C 8 ) alkyl, - (CR78R79) o -R12, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, CO - (C 1 -C 8 ) alkyl, -CO- (CH 2 ) o -R12, O (C (R15) (R16)) q N (R17) (R18); or R1 and R2 form, together with the nitrogen atom to which they are bonded, a 4-10 membered mono- or bicyclic ring, which, in addition to the nitrogen atom, may contain 0-2 additional heteroatoms selected from the group consisting of oxygen and nitrogen, where the heterocyclic ring system may be further substituted with F, (C 1 -C 6 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, oxo, CO (R26), hydroxy, N (R31) ( R32); o имеет значение 0, 1, 2, 3;o has a value of 0, 1, 2, 3; q имеет значение 1 или 2;q is 1 or 2; R15, R16, R17, R26, R31, R32, независимо друг от друга, представляют собой H, (C1-C6)алкил;R15, R16, R17, R26, R31, R32, independently of one another, are H, (C 1 -C 6 ) alkyl; R18 представляет собой H, (C1-C6)алкил; илиR18 represents H, (C 1 -C 6 ) alkyl; or R17 и R18, R21 и R22, R27 и R28, R31 и R32, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, выбранное из пирролидина, пиперидина, N-метилпиперазина, морфолина;R17 and R18, R21 and R22, R27 and R28, R31 and R32, independently of each other, optionally together with the nitrogen atom to which they are attached, form a 5-6 membered ring selected from pyrrolidine, piperidine, N-methylpiperazine, morpholine; R12 представляет собой OH, O-(C1-C6)алкил, 3-10-членное моно- или бициклическое кольцо, которое может содержать 1-2 гетероатома, выбранных из группы, включающей N, O и S, и указанное 3-10-членное кольцо может содержать дополнительные заместители, такие как F, OH, оксо, (C1-C6)алкил, CO(C1-C6)алкил,;R12 represents OH, O- (C 1 -C 6 ) alkyl, a 3-10 membered mono- or bicyclic ring, which may contain 1-2 heteroatoms selected from the group consisting of N, O and S, and said 3- The 10 membered ring may contain additional substituents, such as F, OH, oxo, (C 1 -C 6 ) alkyl, CO (C 1 -C 6 ) alkyl ,; R78, R79, независимо друг от друга, представляют собой H, (C1-C8)алкил, гидрокси-(C1-C4)алкил, OH, (C1-C4)алкокси-(C1-C4)алкил;R78, R79, independently of one another, are H, (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, OH, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl; R3 представляет собой H;R3 represents H; R4, R5, независимо друг от друга, представляют собой H, OH, O-(C1-C6)алкил;R4, R5, independently of one another, are H, OH, O- (C 1 -C 6 ) alkyl; R6, R7, R8, R9, представляют собой H;R6, R7, R8, R9 are H; n имеет значение 1;n is 1; m имеет значение 1;m is 1; A, B, D, G представляют собой C(R42);A, B, D, G are C (R42); R42 представляет собой H, F, Cl, CF3, CN, (C1-C6)алкил, -(CR84R85)x-O(R86);R42 represents H, F, Cl, CF 3 , CN, (C 1 -C 6 ) alkyl, - (CR84R85) x —O (R86); R84, R85 представляют собой H;R84, R85 are H; R86 представляет собой H, (C1-C6)алкил;R86 is H, (C 1 -C 6 ) alkyl; x имеет значение 0, 1, 2; предпочтительно, 0, 1; особенно предпочтительно 1;x has the value 0, 1, 2; preferably 0, 1; particularly preferably 1; R10 представляет собой H, (C1-C8)алкил;R10 represents H, (C 1 -C 8 ) alkyl; X представляет собой связь, C=C, C(R53)(R54), СН2-СН2;X is a bond, C = C, C (R53) (R54), CH 2 —CH 2 ; R53, R54, независимо друг от друга, представляют собой H, (C1-C8)алкил;R53, R54, independently of one another, are H, (C 1 -C 8 ) alkyl; E выбран из группы, включающейE is selected from the group including
Figure 00000005
Figure 00000005
 которые могут необязательно содержать заместители, выбранные из группы, включающей H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)алкил, (C1-C6)алкил, (C2-C6)алкенил, N(R57)(R58), SO2-CH3, CO(R65);which may optionally contain substituents selected from the group consisting of H, F, Cl, Br, OH, CF 3 , NO 2 , OCF 3 , O- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, N (R57) (R58), SO 2 -CH 3 , CO (R65); R57, R58, независимо друг от друга, представляют собой H, (C1-C8)алкил;R57, R58, independently of one another, are H, (C 1 -C 8 ) alkyl; R65, независимо друг от друга, представляют собой H, (C1-C8)алкил;R65, independently of one another, are H, (C 1 -C 8 ) alkyl; K представляет собой связь, O, OCH2, CH2O, CON(R68), (C(R69)(R70))v, CO, C≡C;K is a bond, O, OCH 2 , CH 2 O, CON (R68), (C (R69) (R70)) v , CO, C≡C; v имеет значение 1, 2;v has a value of 1, 2; R68, R69, R70, независимо друг от друга, представляют собой H, (C1-C8)алкил;R68, R69, R70, independently of one another, are H, (C 1 -C 8 ) alkyl; R11 представляет собой (C1-C8)алкил, (C1-C4)алкокси-(C1-C4)алкил, 3-10-членное моно- или бициклическое кольцо, которое может содержать 0-2 гетероатома, выбранных из группы, включающей кислород, азот и серу, где указанная кольцевая система может быть дополнительно замещена F, Cl, Br, CF3, CN, (C1-C6)алкилом, O-(C1-C8)алкилом, оксо, CO(R71), CON(R72)(R73), N(R75)CO(C1-C6)алкилом или SO2CH3;R11 is a (C 1 -C 8 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, 3-10 membered mono- or bicyclic ring, which may contain 0-2 heteroatoms selected from the group comprising oxygen, nitrogen and sulfur, where the specified ring system may be further substituted by F, Cl, Br, CF 3 , CN, (C 1 -C 6 ) alkyl, O- (C 1 -C 8 ) alkyl, oxo , CO (R71), CON (R72) (R73), N (R75) CO (C 1 -C 6 ) alkyl or SO 2 CH 3 ; R71, R72, R75, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR71, R72, R75, independently of one another, are H, (C 1 -C 8 ) alkyl; or R72 и R73, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, илиR72 and R73, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group consisting of N- (C 1 -C 6 ) alkyl, oxygen and sulfur, or их N-оксиды и физиологически приемлемые соли.their N-oxides and physiologically acceptable salts. 4. Соединение по п.1, отличающееся тем, что имеет формулу (Ia)4. The compound according to claim 1, characterized in that it has the formula (Ia)
Figure 00000006
Figure 00000006
 R1, R2, независимо друг от друга, представляют собой H, (C1-C8)алкил, -(CR78R79)o-R12, (C1-C4)алкокси-(C1-C4)алкил, или R1 и R2 образуют вместе с атомом азота, с которым они связаны, 4-10-членное моно-, би- или спироциклическое кольцо, которое, помимо атома азота, может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей кислород, азот и серу, где гетероциклическая кольцевая система может быть дополнительно замещена F, (C1-C6)алкилом, О-(С1-С4)алкилом, (C1-C4)алкокси-(C1-C4)алкилом, гидрокси-(C1-C4)алкилом, (C0-C2)алкиленарилом, оксо, CO(R26), CON(R27)(R28), гидрокси, N(R31)(R32) или SO2CH3; где R1 и R2 оба не являются СО(R26);R1, R2, independently of one another, are H, (C 1 -C 8 ) alkyl, - (CR78R79) o-R12, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, or R1 and R2 form, together with the nitrogen atom to which they are bonded, a 4-10 membered mono-, bi- or spirocyclic ring, which, in addition to the nitrogen atom, may contain 0-2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system may be further substituted with F, (C 1 -C 6 ) alkyl, O- (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, hydroxy (C 1 -C 4) alkyl, (C 0 -C 2) alkilenarilom, oxo, CO (R26), CON ( R27) (R28), idroksi, N (R31) (R32) or SO 2 CH 3; where R 1 and R 2 are not both CO (R26); o имеет значение 0, 1, 2, 3, 4;o has the value 0, 1, 2, 3, 4; q имеет значение 1, 2, 3;q is 1, 2, 3; s имеет значение 0, 1, 2;s is 0, 1, 2; R15, R16, R17, R18, R23, R24, R25, R26, R27, R28, R31, R32, независимо друг от друга, представляют собой H, (C1-C6)алкил; илиR15, R16, R17, R18, R23, R24, R25, R26, R27, R28, R31, R32, independently of one another, are H, (C1-C6) alkyl; or R17 и R18, R27 и R28, R31 и R32, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу;R17 and R18, R27 and R28, R31 and R32, independently of each other, optionally together with the nitrogen atom to which they are attached form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatom selected from the group comprising N- (C 1 -C 6 ) alkyl, oxygen and sulfur; R12 представляет собой OH, O-(C1-C6)алкил, O(C0-C2)алкиленарил, CN, S-(C1-C6)алкил, 3-12 членное моно-, би- или спироциклическое кольцо, которое может содержать 1-3 гетероатома, выбранных из группы, включающей N, O и S, и указанное 3-12 членное кольцо может содержать дополнительные заместители, такие как F, OH, CF3, CN, оксо, (C1-C6)алкил, (C0-C2)алкиленарил, N(R34)(R35), COO(R40), CO(C1-C6)алкил;R12 is OH, O- (C 1 -C 6 ) alkyl, O (C 0 -C 2 ) alkylene aryl, CN, S- (C 1 -C 6 ) alkyl, 3-12 membered mono-, bi- or spirocyclic a ring which may contain 1-3 heteroatoms selected from the group consisting of N, O and S, and said 3-12 membered ring may contain additional substituents, such as F, OH, CF 3 , CN, oxo, (C 1 - C 6 ) alkyl, (C 0 -C 2 ) alkylenearyl, N (R34) (R35), COO (R40), CO (C 1 -C 6 ) alkyl; R34, R35, независимо друг от друга, представляют собой H, (C1-C4)алкил;R34, R35, independently of one another, are H, (C 1 -C 4 ) alkyl; R40 представляет собой H, (C1-C6)алкил, (C0-C2)алкиленарил;R40 represents H, (C 1 -C 6 ) alkyl, (C 0 -C 2 ) alkylene aryl; R78, R79, независимо друг от друга, представляют собой H, (C1-C8)алкил, гидрокси-(C1-C4)алкил, OH, (C1-C4)алкокси-(C1-C4)алкил;R78, R79, independently of one another, are H, (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, OH, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl; R42, R42', независимо друг от друга, представляют собой H, F, Cl, Br, CF3, CN, (C1-C6)алкил;R42, R42 ', independently of one another, are H, F, Cl, Br, CF 3 , CN, (C 1 -C 6 ) alkyl; R10 представляет собой H, (C1-C8)алкил;R10 represents H, (C 1 -C 8 ) alkyl; X представляет собой N(R52), связь, C=C, C(R53)(R54), СН2СН2;X represents N (R52), a bond, C = C, C (R53) (R54), CH 2 CH 2 ; R52, R53, R54, независимо друг от друга, представляют собой H, (C1-C8)алкил;R52, R53, R54, independently of one another, are H, (C 1 -C 8 ) alkyl; E выбран из группы, включающейE is selected from the group including
Figure 00000004
Figure 00000004
 которые могут необязательно содержать заместители, выбранные из группы, включающей H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)алкил, (C1-C6)алкил, (C2-C6)алкенил, N(R57)(R58), SO2-CH3, CO(R65);which may optionally contain substituents selected from the group consisting of H, F, Cl, Br, OH, CF 3 , NO 2 , OCF 3 , O- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, N (R57) (R58), SO 2 -CH 3 , CO (R65); R57, R58, независимо друг от друга, представляют собой H, (C1-C8)алкил;R57, R58, independently of one another, are H, (C 1 -C 8 ) alkyl; R65 представляют собой H, (C1-C8)алкил;R65 is H, (C 1 -C 8 ) alkyl; K представляет собой связь, O, OCH2, CH2O, S, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C≡C, SCH2, SO2CH2;K is a bond, O, OCH 2 , CH 2 O, S, SO 2 , N (R66), N (R67) CO, CON (R68), (C (R69) (R70)) v , CO, C≡ C, SCH 2 , SO 2 CH 2 ; v имеет значение 1, 2, 3;v has a value of 1, 2, 3; R66, R67, R68, R69, R70, независимо друг от друга, представляют собой H, (C1-C8)алкил;R66, R67, R68, R69, R70, independently of one another, are H, (C 1 -C 8 ) alkyl; R11 представляет собой (C1-C8)алкил, (C1-C4)алкокси-(C1-C4)алкил, 3-10-членное моно-, би-, три- или спироциклическое кольцо, которое может содержать 0-4 гетероатома, выбранных из группы, включающей кислород, азот и серу, где указанная кольцевая система может быть дополнительно замещена F, Cl, Br, CF3, CN, (C1-C6)алкилом, O-(C1-C8)алкилом, оксо, CO(R71), гидрокси, N(R75)CO(C1-C6)алкилом или SO2CH3;R11 represents a (C 1 -C 8) alkyl, (C 1 -C 4) alkoxy- (C 1 -C 4) -alkyl, 3-10 membered mono-, bi-, tri- or spirocyclic ring which may comprise 0-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, wherein said ring system may be further substituted with F, Cl, Br, CF 3 , CN, (C 1 -C 6 ) alkyl, O- (C 1 - C 8 ) alkyl, oxo, CO (R71), hydroxy, N (R75) CO (C 1 -C 6 ) alkyl or SO 2 CH 3 ; R71, R72, R73, R74, R75, R76, R77, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR71, R72, R73, R74, R75, R76, R77, independently of one another, are H, (C 1 -C 8 ) alkyl; or R72 и R73, R76 и R77, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, илиR72 and R73, R76 and R77, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group including N- (C 1 -C 6 ) alkyl, oxygen and sulfur, or их N-оксиды и физиологически приемлемые соли.their N-oxides and physiologically acceptable salts. 5. Соединение по п.1, отличающееся тем, что имеет формулу (Ib)5. The compound according to claim 1, characterized in that it has the formula (Ib)
Figure 00000007
Figure 00000007
 где R1, R2, независимо друг от друга, представляют собой H, (C1-C8)алкил, -(CR78R79)o-R12, (C1-C4)алкокси-(C1-C4)алкил, (C3-C8)алкенил, CO-(C1-C8)алкил, -CO-(CH2)o-R12, CO-арилокси-(C1-C4)алкил, COCH=CH(R13), COCC(R14), CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22), CO(C(R23)(R24))sO(R25); или R1 и R2 образуют вместе с атомом азота, с которым они связаны, 4-10-членное моно-, би- или спироциклическое кольцо, которое, помимо атома азота, может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей кислород, азот и серу, где гетероциклическая кольцевая система может быть дополнительно замещена F, Cl, CF3, (C1-C6)алкилом, O-(C1-C4)алкилом, (C1-C4)алкокси-(C1-C4)алкилом, гидрокси-(C1-C4)алкилом, (C0-C2)алкиленарилом, оксо, CO(R26), CON(R27)(R28), гидрокси, COO(R29), N(R30)CO(C1-C6)алкилом, N(R31)(R32) или SO2CH3, где R1 и R2 оба не являются CO(R26);where R1, R2, independently of one another, are H, (C 1 -C 8 ) alkyl, - (CR78R79) o -R12, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, ( C 3 -C 8 ) alkenyl, CO- (C 1 -C 8 ) alkyl, -CO- (CH 2 ) o -R12, CO-aryloxy- (C 1 -C 4 ) alkyl, COCH = CH (R13), COCC (R14), CO (C (R15) (R16)) q N (R17) (R18), CO (C (R19) (R20)) r CON (R21) (R22), CO (C (R23) ( R24)) s O (R25); or R1 and R2 form, together with the nitrogen atom to which they are attached, a 4-10 membered mono-, bi- or spirocyclic ring, which, in addition to the nitrogen atom, may contain 0-2 additional heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur, where the heterocyclic ring system may be further substituted with F, Cl, CF 3 , (C 1 -C 6 ) alkyl, O- (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, (C 0 -C 2 ) alkylene aryl, oxo, CO (R26), CON (R27) (R28), hydroxy, COO (R29), N (R30) CO (C 1 -C 6 ) alkyl, N (R31) (R32) or SO 2 CH 3 , where R1 and R2 are not both CO (R26); o имеет значение 0, 1, 2, 3, 4, 5, 6;o has the value 0, 1, 2, 3, 4, 5, 6; q, r, независимо друг от друга, имеют значение 1, 2, 3;q, r, independently of each other, have a value of 1, 2, 3; s имеет значение 0, 1, 2, 3, 4;s is 0, 1, 2, 3, 4; R13, R14, независимо друг от друга, представляют собой другое фенильное кольцо, которое может содержать 0-1 атом азота;R13, R14, independently of each other, represent another phenyl ring, which may contain 0-1 nitrogen atom; R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, независимо друг от друга, представляют собой H, (C1-C6)алкил;R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, independently of each other, are H, (C 1 -C 6 ) alkyl; R18 представляет собой H, (C1-C6)алкил, СО-(C1-C6)алкил, CO(R33); илиR18 represents H, (C 1 -C 6 ) alkyl, CO- (C 1 -C 6 ) alkyl, CO (R33); or R17 и R18, R21 и R22, R27 и R28, R31 и R32, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу;R17 and R18, R21 and R22, R27 and R28, R31 and R32, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0 -1 an additional heteroatom selected from the group consisting of N- (C 1 -C 6 ) alkyl, oxygen and sulfur; R33 представляет собой 5-10-членную ароматическую кольцевую систему, которая может содержать дополнительный гетероатом, выбранный из группы, включающей азот, кислород и серу, и может быть замещена F, Cl, (C1-C6)алкилом, O-(C1-C8)алкилом;R33 represents a 5-10 membered aromatic ring system which may contain an additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur and may be substituted with F, Cl, (C 1 -C 6) alkyl, O- (C 1 -C 8 ) alkyl; R12 представляет собой OH, O-(C1-C6)алкил, O(C0-C8)алкиленарил, CN, S-(C1-C6)алкил, COO(R80), CON(R81)(R82), 3-12 членное моно-, би- или спироциклическое кольцо, которое может содержать один или несколько гетероатомов, выбранных из группы, включающей N, O и S, и указанное 3-12 членное кольцо может содержать дополнительные заместители, такие как F, Cl, Br, OH, CF3, CN, оксо, O-(C1-C6)алкил, (C1-C4)алкокси-(C1-C4)алкил, (C1-C6)алкил, O-(C0-C8)алкиленарил, (C0-C8)алкиленарил, N(R34)(R35), COCH=CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), CO(C1-C6)алкил, COCOO(C1-C6)алкил, COO(R40), S(O)u(R41);R12 is OH, O- (C 1 -C 6 ) alkyl, O (C 0 -C 8 ) alkylenearyl, CN, S- (C 1 -C 6 ) alkyl, COO (R80), CON (R81) (R82 ), A 3-12 membered mono-, bi- or spirocyclic ring, which may contain one or more heteroatoms selected from the group consisting of N, O and S, and said 3-12 membered ring may contain additional substituents, such as F, Cl, Br, OH, CF 3 , CN, oxo, O- (C 1 -C 6 ) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, (C 1 -C 6 ) alkyl , O- (C 0 -C 8 ) alkylene aryl, (C 0 -C 8 ) alkylene aryl, N (R34) (R35), COCH = CH (R36), (C (R37) (R38)) t (R39), CO (C (R37) (R38)) t (R39), CO (C 1 -C 6 ) alkyl, COCOO (C 1 -C 6 ) alkyl, COO (R40), S (O) u (R41); t имеет значение 0, 1, 2, 3, 4, 5, 6;t is 0, 1, 2, 3, 4, 5, 6; u имеет значение 0, 1, 2;u has the value 0, 1, 2; R34, R35, R37, R38, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR34, R35, R37, R38, independently of one another, are H, (C 1 -C 8 ) alkyl; or R34 и R35 необязательно вместе с атомом азота, с которым они связаны, образуют 5-6 членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, и может необязательно быть замещенным 1-2 оксогруппами;R34 and R35 optionally together with the nitrogen atom to which they are bonded form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group consisting of N- (C 1 -C 6 ) alkyl, oxygen and sulfur, and may optionally be substituted with 1-2 oxo groups; R36, R39, независимо друг от друга, представляет собой (C3-C8)циклоалкил, 5-10-членную ароматическую кольцевую систему, которая может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей азот, кислород и серу, и может быть замещена F, Cl, (C1-C6)алкилом, O-(C1-C8)алкилом;R36, R39, independently of one another, is a (C 3 -C 8 ) cycloalkyl, 5-10 membered aromatic ring system which may contain 0-2 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and may be substituted with F, Cl, (C 1 -C 6 ) alkyl, O- (C 1 -C 8 ) alkyl; R40 представляет собой H, (C1-C8)алкил, (C2-C6)алкенил, (C0-C8)алкиленарил;R40 represents H, (C 1 -C 8 ) alkyl, (C 2 -C 6 ) alkenyl, (C 0 -C 8 ) alkylenearyl; R41 представляет собой (C1-C6)алкил, 5-10-членную ароматическую кольцевую систему, которая может содержать 0-2 дополнительных гетероатома, выбранных из группы, включающей азот, кислород и серу, и может быть замещена F, Cl, (C1-C6)алкилом, O-(C1-C8)алкилом;R41 is a (C 1 -C 6 ) alkyl, 5-10 membered aromatic ring system that may contain 0-2 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and may be substituted with F, Cl, ( C 1 -C 6 ) alkyl; O- (C 1 -C 8 ) alkyl; R78, R79, независимо друг от друга, представляют собой H, (C1-C8)алкил, гидрокси-(C1-C4)алкил, OH, (C1-C4)алкокси-(C1-C4)алкил;R78, R79, independently of one another, are H, (C 1 -C 8 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, OH, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl; R80, R81, независимо друг от друга, представляют собой H, (C1-C8)алкил;R80, R81, independently of one another, are H, (C 1 -C 8 ) alkyl; R10 представляет собой H, (C1-C8)алкил;R10 represents H, (C 1 -C 8 ) alkyl; E выбран из группы, включающейE is selected from the group including
Figure 00000004
Figure 00000004
 которые могут необязательно содержать заместители, выбранные из группы, включающей H, F, Cl, Br, OH, CF3, NO2, OCF3, O-(C1-C6)алкил, (C1-C6)алкил, (C2-C6)алкенил, N(R57)(R58), SO2-CH3, CO(R65);which may optionally contain substituents selected from the group consisting of H, F, Cl, Br, OH, CF 3 , NO 2 , OCF 3 , O- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, N (R57) (R58), SO 2 -CH 3 , CO (R65); R57, R58, независимо друг от друга, представляют собой H, (C1-C8)алкил;R57, R58, independently of one another, are H, (C 1 -C 8 ) alkyl; R65, независимо друг от друга, представляют собой H, (C1-C8)алкил, арил;R65, independently of one another, are H, (C 1 -C 8 ) alkyl, aryl; K представляет собой связь, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, С=С, C≡C, SCH2, SO2CH2;K is a bond, O, OCH 2, CH 2 O, S, SO, SO 2, N (R66), N ( R67) CO, CON (R68), (C (R69) (R70)) v, CO, C = C, C≡C, SCH 2 , SO 2 CH 2 ; v имеет значение 1, 2, 3, 4;v is 1, 2, 3, 4; R66, R67, R68, R69, R70, независимо друг от друга, представляют собой H, (C1-C8)алкил;R66, R67, R68, R69, R70, independently of one another, are H, (C 1 -C 8 ) alkyl; R11 представляет собой (C1-C8)алкил, (C1-C4)алкокси-(C1-C4)алкил, (С3-С8)алкенил, (С3-С8)алкинил, 3-10-членное моно-, би-, три- или спироциклическое кольцо, которое может содержать 0-4 гетероатома, выбранных из группы, включающей кислород, азот и серу, где указанная кольцевая система может быть дополнительно замещена F, Cl, Br, CF3, CN, (C1-C6)алкилом, O-(C1-C8)алкилом, (С1-С4)алкокси-(С1-С4)алкилом, гидрокси-(С1-С4)алкилом, (С0-С8)алкиленарилом, оксо, CO(R71), CON(R73)(R73), гидрокси, COO(R74), N(R75)CO(C1-C6)алкилом, N(R76)(R77) или SO2CH3;R11 is (C1-C8) alkyl, (C1-C4) alkoxy- (C1-C4) alkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 ) alkynyl, 3-10 membered mono, a bi-, tri- or spirocyclic ring, which may contain 0-4 heteroatoms selected from the group comprising oxygen, nitrogen and sulfur, where said ring system may be further substituted by F, Cl, Br, CF 3 , CN, (C1- C6) alkyl, O- (C1-C8) alkyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) alkyl, hydroxy- (C 1 -C 4 ) alkyl, (C 0 -C 8 ) alkylene aryl oxo, CO (R71), CON (R73) (R73), hydroxy, COO (R74), N (R75) CO (C1-C6) alkyl, N (R76) (R77) or SO 2 CH 3 ; R71, R72, R73, R74, R75, R76, R77, независимо друг от друга, представляют собой H, (C1-C8)алкил; илиR71, R72, R73, R74, R75, R76, R77, independently of one another, are H, (C1-C8) alkyl; or R72 и R73, R76 и R77, независимо друг от друга, необязательно вместе с атомом азота, с которым они связаны, образуют 5-6-членное кольцо, которое, помимо атома азота, может также содержать 0-1 дополнительный гетероатом, выбранный из группы, включающей N-(C1-C6)алкил, кислород и серу, илиR72 and R73, R76 and R77, independently of each other, optionally together with the nitrogen atom to which they are bonded, form a 5-6 membered ring, which, in addition to the nitrogen atom, may also contain 0-1 additional heteroatoms selected from the group including N- (C1-C6) alkyl, oxygen and sulfur, or их N-оксиды и физиологически приемлемые соли.their N-oxides and physiologically acceptable salts. 6. Лекарственное средство, включающее одно или несколько соединений по пп.1-5.6. A medicine comprising one or more compounds according to claims 1-5. 7. Лекарственное средство, включающее одно или несколько соединений по пп.1-5 и один или несколько анорексически активных ингредиентов.7. A medicament comprising one or more compounds according to claims 1-5 and one or more anorexic active ingredients. 8. Соединение формулы (I) по пп.1-5 для применения в качестве лекарственного средства для профилактики и лечения ожирения.8. The compound of formula (I) according to claims 1-5 for use as a medicine for the prevention and treatment of obesity. 9. Соединение формулы (I) по пп.1-5 для применения в качестве лекарственного средства для профилактики и лечения диабета типа II.9. The compound of formula (I) according to claims 1-5 for use as a medicine for the prevention and treatment of type II diabetes. 10. Соединение формулы (I) по пп.1-5 в сочетании с по меньшей мере одним дополнительным анорексически активным ингредиентом для применения в качестве лекарственного средства для профилактики и лечения ожирения.10. The compound of formula (I) according to claims 1-5 in combination with at least one additional anorexic active ingredient for use as a medicament for the prevention and treatment of obesity. 11. Соединение формулы (I) по пп.1-5 в сочетании с по меньшей мере одним дополнительным анорексически активным ингредиентом для применения в качестве лекарственного средства для профилактики и лечения диабета типа II.11. The compound of formula (I) according to claims 1-5 in combination with at least one additional anorexic active ingredient for use as a medicament for the prevention and treatment of type II diabetes. 12. Способ получения лекарственного средства, включающего одно или несколько соединений формулы (I) по пп.1-5, который включает смешивание активного ингредиента с фармацевтически приемлемым носителем и преобразование полученной смеси в форму, подходящую для введения.12. A method for producing a medicament comprising one or more compounds of formula (I) according to claims 1-5, which comprises mixing the active ingredient with a pharmaceutically acceptable carrier and converting the resulting mixture into a form suitable for administration. 13. Применение соединения формулы (I) по пп.1-5 для получения лекарственного средства для снижения массы у млекопитающих.13. The use of the compounds of formula (I) according to claims 1-5 for the preparation of a medicament for weight loss in mammals. 14. Применение соединения формулы (I) по пп.1-5 для получения лекарственного средства для профилактики и лечения ожирения.14. The use of the compounds of formula (I) according to claims 1-5 for the manufacture of a medicament for the prevention and treatment of obesity. 15. Применение соединения формулы (I) по пп.1-5 для получения лекарственного средства для профилактики и лечения диабета типа II.15. The use of the compounds of formula (I) according to claims 1-5 for the manufacture of a medicament for the prevention and treatment of type II diabetes. 16. Применение соединения формулы (I) по пп.1-5 для получения лекарственного средства для лечения тревожности и других психиатрических показаний, для лечения расстройств, связанных с циркадным ритмом, и для лечения злоупотребления лекарственными средствами.16. The use of the compounds of formula (I) according to claims 1-5 for the manufacture of a medicament for the treatment of anxiety and other psychiatric indications, for the treatment of circadian rhythm disorders, and for the treatment of drug abuse. 17. Применение соединения формулы (I) по пп.1-5 для получения лекарственного средства, обладающего активностью антагониста МСН-рецептора.17. The use of the compounds of formula (I) according to claims 1-5 for the preparation of a medicament having an MCH receptor antagonist activity.
RU2005128551/04A 2003-02-14 2004-02-13 SUBSTITUTED N-ARILGETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR APPLICATION AS MEDICINES RU2005128551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10306250.5 2003-02-14
DE10306250A DE10306250A1 (en) 2003-02-14 2003-02-14 Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
RU2005128551A true RU2005128551A (en) 2006-02-10

Family

ID=32841665

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005128551/04A RU2005128551A (en) 2003-02-14 2004-02-13 SUBSTITUTED N-ARILGETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR APPLICATION AS MEDICINES

Country Status (29)

Country Link
EP (1) EP1597228A2 (en)
JP (1) JP2006517563A (en)
KR (1) KR20050101215A (en)
CN (1) CN100506792C (en)
AR (1) AR044496A1 (en)
AU (1) AU2004212145B2 (en)
BR (1) BRPI0407504A (en)
CA (1) CA2516118A1 (en)
CO (1) CO5690548A2 (en)
DE (1) DE10306250A1 (en)
EC (1) ECSP055967A (en)
HR (1) HRP20050710A2 (en)
MA (1) MA27735A1 (en)
MX (1) MXPA05008449A (en)
MY (1) MY139102A (en)
NO (1) NO20054220L (en)
NZ (1) NZ541823A (en)
OA (1) OA13027A (en)
PA (1) PA8595901A1 (en)
PE (1) PE20040952A1 (en)
PL (1) PL378065A1 (en)
RS (1) RS20050666A (en)
RU (1) RU2005128551A (en)
TN (1) TNSN05194A1 (en)
TW (1) TW200510297A (en)
UA (1) UA86760C2 (en)
UY (1) UY28186A1 (en)
WO (1) WO2004072025A2 (en)
ZA (1) ZA200506369B (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
KR20060025141A (en) 2003-05-15 2006-03-20 아르퀼 인코포레이티드 Inhibitors of p38 and methods of using the same
ES2327684T3 (en) * 2003-07-24 2009-11-02 Euro-Celtique S.A. HETEROARIL-TETRAHIDROPIRIDILO COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF PAIN.
EP1867644B1 (en) * 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
US7632950B2 (en) * 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (en) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New amide compounds having MCH antagonist activity and medicaments containing these compounds
DE102004003812A1 (en) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
WO2006022442A1 (en) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TW200626138A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2582327A1 (en) * 2004-10-01 2006-04-13 Takao Suzuki 2-arylcarboxamide-nitrogeneous heterocycle compound
MX2007004661A (en) * 2004-10-18 2007-06-22 Lilly Co Eli 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists.
EP1809636A1 (en) 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
DE102004051277A1 (en) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclic carbonyl compounds
JPWO2006054793A1 (en) * 2004-11-19 2008-06-05 財団法人新産業創造研究機構 Benzofuran compound and pharmaceutical composition containing the same
UA89514C2 (en) 2004-12-30 2010-02-10 Janssen Pharmaceutica Nv Derivatives of 4-(benzyl)-piperazine-1-carboxylic acid phenylamides and related compounds as modulators of fatty acid amide hydrolase for the treatment of anxiety, pain and other states
AU2006208043B2 (en) * 2005-01-25 2012-09-20 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
BRPI0616646A2 (en) 2005-09-30 2011-06-28 Hoffmann La Roche compounds, pharmaceutical composition, use and manufacturing process of selective mch receptor antagonists
US7820821B2 (en) 2006-02-10 2010-10-26 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
KR20080096670A (en) * 2006-02-15 2008-10-31 사노피-아벤티스 Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
WO2007093363A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
WO2007123269A1 (en) * 2006-04-19 2007-11-01 Astellas Pharma Inc. Azolecarboxamide derivative
EA018917B1 (en) 2006-04-19 2013-11-29 Новартис Аг 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
ES2555515T3 (en) 2006-05-08 2016-01-04 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
CN101506203B (en) * 2006-08-24 2013-10-16 诺瓦提斯公司 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other syndromes
PE20081368A1 (en) 2006-09-11 2008-11-19 Glaxo Group Ltd DERIVATIVES OF AZABICYCLE [4.1.0] HEPTANE AS INHIBITORS OF THE RECAPTATION OF SEROTONIN, DOPAMINE AND NOREPINEPHRINE
WO2008039794A1 (en) * 2006-09-25 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
PE20080888A1 (en) * 2006-10-18 2008-08-26 Novartis Ag HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)
WO2008086014A2 (en) * 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
RU2470017C2 (en) * 2007-06-08 2012-12-20 Янссен Фармацевтика Н.В. Piperidine/piperazine derivatives
WO2008148851A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
TWI452044B (en) 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp Morpholine derivative
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
ES2356032T3 (en) 2007-09-14 2011-04-04 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-PHENYL-3,4,5,6-TETRAHIDRO-2H, 1'H- [1,4 '] BIPIRIDINIL-2'-ONAS 1,3'-DISUSTITUTED.
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
KR20100065191A (en) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
PT2215058E (en) * 2007-10-17 2012-03-06 Sanofi Sa Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
PT2212282E (en) * 2007-10-17 2012-01-09 Sanofi Sa Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MX2010003949A (en) * 2007-10-17 2010-04-30 Sanofi Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof.
MY150210A (en) * 2007-10-17 2013-12-13 Sanofi Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
ES2498065T3 (en) 2007-10-24 2014-09-24 Astellas Pharma Inc. Azolcarboxamide compound or salt thereof
ES2637794T3 (en) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Imidazo [1,2-A] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2070916A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
EP2070925A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
EP2070924A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
RU2364597C1 (en) 2007-12-14 2009-08-20 Андрей Александрович Иващенко HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM
US9107946B2 (en) * 2008-06-05 2015-08-18 Janssen Pharmaceutica Nv Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP5547194B2 (en) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors
EP2334181A4 (en) * 2008-09-16 2012-03-14 Merck Sharp & Dohme Phthalimide derivative metabotropic glutamate r4 ligands
JP2012006837A (en) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2-indoleacrylamide analogue
CN102186477B (en) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010056311A1 (en) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
RU2512283C2 (en) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AR074466A1 (en) * 2008-12-05 2011-01-19 Sanofi Aventis PIPERIDINE ESPIRO PIRROLIDINONA AND PIPERIDINONA REPLACED AND ITS THERAPEUTIC USE IN DISEASES MEDIATED BY THE MODULATION OF H3 RECEPTORS.
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2010101247A1 (en) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Cyclohexane derivative having npy y5 receptor antagonism
EP2404902A1 (en) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430031B1 (en) 2009-05-12 2013-04-17 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
BR112012003973A2 (en) 2009-08-26 2015-09-08 Sanofi Sa crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011060026A1 (en) 2009-11-12 2011-05-19 Jansen Pharmaceutica Nv Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
WO2011143150A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
JP5833105B2 (en) * 2010-05-11 2015-12-16 サノフイ Substituted N-heteroaryl spirolactam bipyrrolidines, their preparation and therapeutic use
EP2569294B1 (en) * 2010-05-11 2015-03-11 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
UY33469A (en) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103261195B (en) 2010-11-08 2015-09-02 杨森制药公司 The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof
ES2552879T3 (en) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8957093B2 (en) 2011-06-06 2015-02-17 The Scripps Research Institute N-biphenylmethylindole modulators of PPARG
WO2012170561A1 (en) * 2011-06-06 2012-12-13 The Scripps Research Institute (T.S.R.I.) N-benzylindole modulators of pparg
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
US9238658B2 (en) 2011-12-06 2016-01-19 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors
WO2013085957A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
JP2015516436A (en) * 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド NAMPT inhibitor
JP6293770B2 (en) 2012-11-05 2018-03-14 ナント ホールディングス アイピー，エルエルシー Cyclic sulfonamide-containing derivatives as hedgehog signaling pathway inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
CN105102448B (en) 2013-02-28 2018-03-06 百时美施贵宝公司 Phenylpyrazole derivatives as ROCK1 and ROCK2 inhibitor
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MX2016009471A (en) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use.
PT3096790T (en) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
CA2952557A1 (en) * 2014-07-16 2016-01-21 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
JP6633618B2 (en) * 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tideback benzamide derivatives as potent ROCK inhibitors
AU2015315167A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamide compounds
WO2017037595A1 (en) * 2015-08-28 2017-03-09 Glenmark Pharmaceuticals S.A. Novel carbocyclic compounds as ror gamma modulators
MA43706B1 (en) 2016-03-17 2020-09-30 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as a taar agonist
CN108815167B (en) * 2017-05-24 2021-04-13 四川晶华生物科技有限公司 Application of compound in preparing medicine for treating tumor
TW202136238A (en) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 ROR[gamma]T inhibitor, preparation method therefor and use thereof
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
CN115160269A (en) * 2021-04-02 2022-10-11 北京大学 Arylcarboxamide derivatives as positive allosteric modulators of NMDAR
AU2023208684A1 (en) 2022-01-18 2024-09-05 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (en) 1990-06-18 1992-09-04 Adir NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
NZ293741A (en) * 1994-10-26 1998-06-26 Upjohn Co 3-[4-(azetidin-1-yl or pyrrolidin-1-yl)phenyl]-5-aminomethyloxazolidin-2-one amide derivatives
JP3071832B2 (en) 1996-01-17 2000-07-31 ノボ ノルディスク アクティーゼルスカブ Condensed 1,2,4-thiadiazine and condensed 1,4-thiazine derivatives, their production and use
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
PT944648E (en) 1996-08-30 2007-06-26 Novo Nordisk As Glp-1 derivatives
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
HUP0003999A3 (en) 1997-07-16 2003-03-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
CO4970713A1 (en) 1997-09-19 2000-11-07 Sanofi Synthelabo DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CN1285823A (en) * 1997-11-07 2001-02-28 先灵公司 Phenyl-alkyl-imidazoles as H3 receptor antagonists
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (en) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
BR0008173A (en) * 1999-02-10 2002-10-22 Welfide Corp Amide compound and its use as a technical medical field of the invention
RU2254333C2 (en) * 1999-04-09 2005-06-20 Астразенека Аб Derivatives of adamantane, method for their preparing, pharmaceutical composition based on thereof and methods for treatment
AU3956900A (en) 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
SE9901875D0 (en) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
BR0012752A (en) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuryl piperazines and benzofuril homopiperazines: serotonin agonists
DK1218341T3 (en) 1999-09-01 2005-12-12 Sanofi Aventis Deutschland Sulfonylcarboxamide derivatives, process for their preparation and their use as a drug
ES2287120T3 (en) 2000-04-28 2007-12-16 Asahi Kasei Pharma Corporation NEW BICYCLE COMPOUNDS.
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc Melanocortin receptor agonists
AU2001269370B2 (en) * 2000-07-17 2005-10-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
BR0112856A (en) * 2000-07-31 2003-07-01 Smithkline Beecham Plc Method for treating the disorder, compound or a salt or solvate thereof, process for preparing the disorder, pharmaceutical composition, method of treatment and / or prophylaxis of one or more of the disorders, use of a compound, and method for treatment of diabetes, major depression, manic depression, anxiety, schizophrenia, and sleep disorders in human and non-human mammals
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Biphenylcarboxamides useful as lipid lowering agents
JP2002338537A (en) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp Amide compound and its medicinal use
WO2002098871A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Phenylcarboxamides and process for preparation thereof
WO2002098839A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
AU2002346048A1 (en) * 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
DE10142734A1 (en) 2001-08-31 2003-03-27 Aventis Pharma Gmbh New (((oxazolylalkyl)-cycloalkyl)-alkyl)-benzoic acid derivatives, are peroxisome proliferator activated receptor agonists or antagonists used e.g. for treating lipid metabolism disorders, type II diabetes, syndrome X and obesity
EP1505068A4 (en) * 2002-04-23 2008-03-19 Shionogi & Co PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
JP2004175739A (en) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd Medicinal composition

Also Published As

Publication number Publication date
KR20050101215A (en) 2005-10-20
TNSN05194A1 (en) 2007-06-11
WO2004072025A2 (en) 2004-08-26
BRPI0407504A (en) 2006-02-14
ECSP055967A (en) 2006-01-16
MA27735A1 (en) 2006-02-01
PA8595901A1 (en) 2004-09-16
NO20054220L (en) 2005-10-28
CN100506792C (en) 2009-07-01
CO5690548A2 (en) 2006-10-31
AU2004212145A1 (en) 2004-08-26
PE20040952A1 (en) 2005-02-08
ZA200506369B (en) 2006-07-26
AU2004212145B2 (en) 2010-06-17
UY28186A1 (en) 2004-09-30
CA2516118A1 (en) 2004-08-26
JP2006517563A (en) 2006-07-27
RS20050666A (en) 2007-12-31
MXPA05008449A (en) 2006-05-25
EP1597228A2 (en) 2005-11-23
OA13027A (en) 2006-11-10
AR044496A1 (en) 2005-09-14
NO20054220D0 (en) 2005-09-12
DE10306250A1 (en) 2004-09-09
CN1774418A (en) 2006-05-17
PL378065A1 (en) 2006-02-20
WO2004072025A3 (en) 2004-12-23
TW200510297A (en) 2005-03-16
MY139102A (en) 2009-08-28
UA86760C2 (en) 2009-05-25
HRP20050710A2 (en) 2006-07-31
NZ541823A (en) 2009-01-31

Similar Documents

Publication Publication Date Title
RU2005128551A (en) SUBSTITUTED N-ARILGETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR APPLICATION AS MEDICINES
JP2006517563A5 (en)
ES2149767T5 (en) NEW MEDICAL USE FOR TAQUIQUININE ANTAGONISTS.
RU2214400C2 (en) Derivatives of 1-[(1-substituted-4-piperidinyl)- methyl]-4-piperidine, methods for their preparing, pharmaceutical composition based on thereof and intermediate substances
RU2007109600A (en) ARIL SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR PRODUCING THEM AND THEIR APPLICATION AS MEDICINES
RU2008136898A (en) AZACYCLYL-SUBSTITUTED ARYLDIGIDROISOCHINOLINONES, METHOD FOR PRODUCING THEM AND THEIR USE AS MEDICINES
RU2204561C2 (en) Derivatives of xanthine with terminal aminated alkynol side chains and medicinal agent
CN100567288C (en) 4-tetrazyl-4-the phenylpiperidine derivative that is used for the treatment of pain
RU2006130626A (en) SUBSTITUTED CYCLOGEXYLIMIDAZOLINONES WITH ACTION MODULATING SIT
JP2006501202A5 (en)
EP3737672A1 (en) Benzamide compounds
WO2013065712A1 (en) Diazaspirourea derivative and pharmaceutical use thereof
RU99104152A (en) CYCLIC AMINUM DERIVATIVES
ES2767251T3 (en) Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
RU2012125763A (en) SPIROINDOLINONPYRROLIDINES
US20100099714A1 (en) AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
RU2002128614A (en) Pharmaceutically active derivatives of piperidine, in particular as modulators of chemokine receptor activity
RU2001112421A (en) Benzoylcyclohexanedione, a method for their preparation and their use as herbicides and plant growth regulators
RU2007149317A (en) CYCLIC DERIVATIVE AMINE CONTAINING A SUBSTITUTED ALKYL GROUP
RU2006132463A (en) HEMOKIN RECEPTOR ANTAGONISTS
WO2006088193A1 (en) Anti-tumor agent
RU2005104435A (en) DERIVATIVES OF 1-HETEROCYCLYLalkyl-3-SULFONILAZINDOL OR - AZAINDAZOLE AS 5-HYDROXYTRIPTAMINE-6 LIGANDS
PE20030257A1 (en) 8-AZA-11-DEOXY-PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS
AR036939A1 (en) ANTAGONISTS OF THE MELANINE CONCENTRATION HORMONE (MCH) PHARMACEUTICAL COMPOSITIONS, A PROCESS FOR THEIR DEVELOPMENT AND THE USE OF SUCH COMPOUNDS, ONLY OR IN COMBINATION, FOR THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY
AR064253A1 (en) BICYCLOCARBOXYAMIDE COMPOUNDS REPLACED PHARMACEUTICAL COMPOSITIONS AND A COMBINATION THAT INCLUDES THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE RECEIVER'S ACTIVITY VR1

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090619

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090619